May 24, 2018

Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01

Oslo, Norway, 24 May 2018 - Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid...
Read more
May 24, 2018

BONESUPPORT Signs Strategic Agreement with Collagen Matrix, Inc. to Expand Product Offering in the US

Lund, Sweden, 13.00 CET, 24 May 2018 – BONESUPPORT, announces an agreement with Collagen Matrix, Inc. that will allow it to expand its US offering with products that are co...
Read more
May 22, 2018

Nexstim Plc – first NBT® system for depression ordered in the US

Company announcement, Helsinki, 22 May 2018, at 9:00 AM Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and commerci...
Read more
May 22, 2018

Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial

Study Met All Primary and Secondary Endpoints Across Multiple Measures of Breathing and Quality of Life One Year After Treatment SAN DIEGO and REDWOOD CITY, Calif. – May 22, 2...
Read more
May 17, 2018

BioClin Therapeutics Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

(San Leandro, California, May 17, 2018) BioClin Therapeutics, Inc., a clinical stage drug development company announced today that data will be presented from its ongoing Phase 1...
Read more
May 17, 2018

BONESUPPORT creates its own US Commercial Platform

Lund, Sweden, 08.45 CET, 17 May 2018 – BONESUPPORT HOLDING AB (publ) announces today that the current distribution agreement has been terminated and will be replaced by a ne...
Read more
May 16, 2018

Onxeo Provides Business Update and Reports First Quarter 2018 Financial Information

Development of lead product candidate, AsiDNA™, for the treatment of advanced solid tumors, progressing according to plan DRIIV phase I clinical trial ongoing Interim res...
Read more
May 16, 2018

Wilson Therapeutics AB (Publ) Interim report January 1 – March 31, 2018

JANUARY 1 – MARCH 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 68.9 M (loss: 31.4) Loss per share, before and after dilution, totaled...
Read more
May 15, 2018

Nordic Nanovector ASA: Invitation to First Quarter 2018 Results Presentation and Webcast

15.05.2018 20:21 Oslo, Norway, 15 May 2018 Nordic Nanovector ASA (OSE: NANO) announces its first quarter 2018 results on Wednesday, 30 May 2018. First Quarter 2018...
Read more
May 15, 2018

Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET GAITHERSBURG, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage i...
Read more